A phase 1 trial of escalating doses of LAIV (SCH 900795) seasonal vaccine in healthy adults.
Phase of Trial: Phase I
Latest Information Update: 22 May 2014
At a glance
- Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Schering-Plough
- 13 Oct 2009 Status changed from active, no longer recruiting to completed according to a Schering-Plough media release.
- 13 Oct 2009 Primary endpoint 'Immunological response' has been met according to a Schering-Plough media release.
- 31 Aug 2009 Status changed from recruiting to active, no longer recruiting, according to a BioDiem media release.